DRUG — Bright Minds Biosciences Balance Sheet
0.000.00%
Last trade - 00:00- CA$935.30m
- CA$852.52m
- 39
- 26
- 86
- 49
Annual balance sheet for Bright Minds Biosciences, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 19.8 | 11.6 | 6.75 | 5.72 | 82.9 |
| Net Total Receivables | 0.11 | 0.156 | 0.037 | 0.05 | 0.413 |
| Prepaid Expenses | |||||
| Total Current Assets | 20 | 11.9 | 6.81 | 5.99 | 84.3 |
| Net Property, Plant And Equipment | — | 0.139 | 0.066 | 0.118 | 0.112 |
| Net Intangible Assets | |||||
| Total Assets | 20 | 12.1 | 6.88 | 6.1 | 84.4 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 0.639 | 1.47 | 0.281 | 0.529 | 2.34 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.639 | 1.54 | 0.281 | 0.568 | 2.38 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 19.4 | 10.5 | 6.6 | 5.54 | 82 |
| Total Liabilities & Shareholders' Equity | 20 | 12.1 | 6.88 | 6.1 | 84.4 |
| Total Common Shares Outstanding |